V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity
CELL REPORTS
Authors: van Eeden, Charmaine; Wibmer, Constantinos Kurt; Scheepers, Cathrine; Richardson, Simone I.; Nonyane, Molati; Lambson, Bronwen; Mkhize, Nonhlanhla N.; Vijayakumar, Balakrishnan; Sheng, Zizhang; Stanfield-Oakley, Sherry; Bhiman, Jinal N.; Bekker, Valerie; Hermanus, Tandile; Mabvakure, Batsirai; Ismail, Arshad; Moody, M. Anthony; Wiehe, Kevin; Garrett, Nigel; Karim, Salim Abdool; Dirr, Heini; Fernandes, Manuel A.; Sayed, Yasien; Shapiro, Lawrence; Ferrari, Guido; Haynes, Barton F.; Moore, Penny L.; Morris, Lynn
Abstract
Antibodies that bind residue K169 in the V2 region of the HIV-1 envelope correlated with reduced risk of infection in the RV144 vaccine trial but were restricted to two ED-motif-encoding light chain genes. Here, we identify an HIV-infected donor with high-titer V2 peptide-binding antibodies and isolate two antibody lineages (CAP228-16H/19F and CAP228-3D) that mediate potent antibody-dependent cell-mediated cytotoxicity (ADCC). Both lineages use the IGHV5-51 heavy chain germline gene, similar to the RV144 antibody CH58, but one lineage (CAP228-16H/19F) uses a light chain without the ED motif. A cocrystal structure of CAP228-16H bound to a V2 peptide identified a IGLV3-21 gene-encoded DDxD motif that is used to bind K169, with a mechanism that allows CAP228-16H to recognize more globally relevant V2 immunotypes. Overall, these data further our understanding of the development of cross-reactive, V2-binding, antiviral antibodies and effectively expand the human light chain repertoire able to respond to RV144-like immunogens.
Quantifying Anti-HIV Envelope-Specific Antibodies in Plasma from HIV Infected Individuals
VIRUSES-BASEL
Authors: Kant, Sanket; Zhang, Ningyu; Routy, Jean-Pierre; Tremblay, Cecile; Thomas, Rejean; Szabo, Jason; Cote, Pierre; Trottier, Benoit; LeBlanc, Roger; Rouleau, Danielle; Harris, Marianne; Dupuy, Franck P.; Bernard, Nicole F.
Abstract
Quantifying HIV Envelope (Env)-specific antibodies in HIV+ plasma is useful for interpreting antibody dependent cellular cytotoxicity assay results. HIV Env, the only viral protein expressed on the surface of infected cells, has a native trimeric closed conformation on cells infected with wild-type HIV. However, CD4(+) uninfected bystander cells in HIV+ cell cultures bind gp120 shed from HIV+ cells exposing CD4-induced epitopes normally hidden in native Env. We used flow-cytometry based assays to quantify antibodies in HIV+ plasma specific for native trimeric Env or gp120/CD4 conjugates using CEM.NKr.CCR5 (CEM) cells infected with HIV (iCEM) or coated with recombinant gp120 (cCEM), as a surrogate for gp120(+) HIV- bystander cells. Results from both assays were compared to those of a plate-based ELISA to monomeric gp120. The levels of Env-specific antibodies to cCEM and iCEM, measured by flow cytometry, and to gp120 by ELISA were positively correlated. More antibodies in HIV+ plasma recognized the gp120 conformation exposed on cCEM than on iCEM. Comparisons of plasma from untreated progressors, treated progressors, and elite controllers revealed that antibodies to Env epitopes were the lowest in treated progressors. Plasma from elite controllers and untreated progressors had similarly high levels of Env-specific antibodies, despite elite controllers having undetectable HIV viral loads, while untreated progressors maintained high viral loads.